Oral News and Research

RSS

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Array BioPharma Inc. today announced presentations on encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 – June 2, 2015 in Chicago, Illinois.

29 May 2015

Practical guidance to ensure safe use of flavourings in e-cigarettes

The first practical guide to ensure the safe use of flavourings in e-cigarettes has been published. E-cigarettes and other vaping products contain a nicotine-based liquid that is vapourised and inhaled. There is no combustion so the user inhales vapour, not smoke. This means that e-cigarettes deliver nicotine without smoke toxicants. However, some in the public health community still have expressed concerns over the potential health impacts of flavourings used in e-cigarettes.

29 May 2015

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.

29 May 2015

MedUni Vienna expert suggests pricing strategy to reduce smoking

30% of the estimated 2.3 million smokers in Austria are considered to be heavily tobacco-dependent and, according to experts at MedUni Vienna, require professional treatment. This would mean around 690,000 people. According to Michael Kunze, an expert on smoking at the Center for Public Health at MedUni Vienna, an effective strategy would be to increase the price of tobacco products: "If the price of cigarettes were to rise just one percent above the inflation rate, that would bring about a 0.5% reduction in consumption worldwide."

29 May 2015

iCo Therapeutics reports financial results for first quarter 2015

iCo Therapeutics, today reported financial results for the quarter ended March 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

Researchers identify chemical pathway associated with seizures, shorter survival in patients with malignant glioma

Researchers at the University of Alabama at Birmingham have identified a chemical pathway that may be associated with seizures and shorter patient survival in some patients with malignant glioma, the most common and deadly form of brain tumor. In findings published May 27 in Science Translational Medicine, the researchers suggest that a transporter known as SXC is responsible for boosting levels of glutamate in the brains of some glioma patients.

28 May 2015

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

World MS Day was created by the Multiple Sclerosis International Foundation (MSIF) in 2009 to raise global awareness of MS...

28 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

28 May 2015

RegenScientific gets FDA approval for Renu Gel injectable implant

RegenScientific announced that it has received FDA-clearance for its Renu Gel injectable implant indicated for vocal fold injection augmentation and today the company commenced shipments of this new product to physicians and hospitals in the United States.

28 May 2015

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis plc announced today that VIBERZI (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist.

28 May 2015

Clinical utility data for Guardant360 platform to be presented at ASCO 2015

Guardant Health today announced that five abstracts submitted by the University of California, San Francisco; University of California, San Diego; and MD Anderson highlighting the performance and clinical utility of Guardant360 have been accepted for oral and poster presentations at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29-June 2.

27 May 2015

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

AbbVie presented new results from the Phase 3 GIFT-I study of its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan.

27 May 2015

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

Detailed data will be presented from the two Phase I trials conducted in 76 healthy volunteers and overweight or obese subjects...

26 May 2015

GHIT Fund expands investments in leishmaniasis, diagnostic tests

The Global Health Innovative Technology Fund, which in the last two years has funded almost $32 million for innovative tools to tackle global infectious diseases, today announced additional investments of nearly $11 million that bring its portfolio to approximately $43 million.

22 May 2015

Research: Some immune cells convert into cells that trigger disease

Researchers at Case Western Reserve University School of Dental Medicine have unraveled one of the mysteries of how a small group of immune cells work: That some inflammation-fighting immune cells may actually convert into cells that trigger disease.

22 May 2015

Women more likely to be hospitalised after asthma emergency care

US research shows that women who attend the emergency department with acute asthma are almost twice as likely to be admitted to hospital than men despite several measures of asthma control, treatment and severity being more favourable in women.

21 May 2015

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension.

21 May 2015

Study shows trophon EPR effective in inactivating high-risk, cancer-causing HPV

A new study presented at the Society for Healthcare Epidemiology of America has demonstrated that the trophon EPR is the only high level disinfection system proven to kill natural, infectious, high-risk human papilloma virus (HPV) under normal use conditions.

20 May 2015

Oral News and Research

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Practical guidance to ensure safe use of flavourings in e-cigarettes

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

MedUni Vienna expert suggests pricing strategy to reduce smoking

iCo Therapeutics reports financial results for first quarter 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Researchers identify chemical pathway associated with seizures, shorter survival in patients with malignant glioma

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

RegenScientific gets FDA approval for Renu Gel injectable implant

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Clinical utility data for Guardant360 platform to be presented at ASCO 2015

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

GHIT Fund expands investments in leishmaniasis, diagnostic tests

Research: Some immune cells convert into cells that trigger disease

Women more likely to be hospitalised after asthma emergency care

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Study shows trophon EPR effective in inactivating high-risk, cancer-causing HPV

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News